本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/11/101 分钟阅读
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
本地自动翻译 · 来源原始语言
摘要
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization…
来源原始语言: GlobeNewswire — Mergers and Acquisitions打开原始公告 →